Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Nov-Dec;62(6):577-82.

[Common variable immunodeficiency. A clinical approach]

[Article in Spanish]
Affiliations
  • PMID: 21416917
Review

[Common variable immunodeficiency. A clinical approach]

[Article in Spanish]
Lizbeth Blancas-Galicia et al. Rev Invest Clin. 2010 Nov-Dec.

Abstract

Common variable immunodeficiency (CVID) is an immunodeficiency characterized by an impaired ability to produce antibodies associated to multiple clinical phenotypes. The incidence is around 1/50,000 new borns. The age at diagnosis shows 2 peaks, between 1-5 and 16-20 years old. The failure is localized in partially mature B lymphocytes, affects antibody synthesis and class switch from IgM to IgG. Only in 10% of cases, a mutation has been detected, in the others, the genetic defect is unknown. The clinical manifestations are severe and recurrent infections, autoimmunity, gastrointestinal manifestations, lymphoid hyperplasia and a high risk to develop cancer. The most common clinical presentation consists in recurrent sinus-bronchial infections. Hemolytic anemia and thrombocytopenia are frequent autoimmune disorders. Diagnosis must be suspected in a patient with sinus-bronchial infections associated to the different clinical syndrome above described, also significant reduction of immunoglobulin G, reduction of immunoglobulin A or immunoglobulin M. The differential diagnosis of CVID is largely based on the exclusion of other antibody immune deficiencies. Mutation on TACI, ICOS, CD19, BAFF-R, MSH5 must be ruled out for molecular diagnosis. Immunoglobulin replacement therapy diminishes the risk of developing pulmonary complications.

PubMed Disclaimer

Similar articles

Cited by

MeSH terms